CoChat
Sign Up
Cited by 1,553

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease

Wu, Mengrui, Chen, Guiqian, Li, Yi-Ping·2016·Bone Research
DOI 10.1038/boneres.2016.9PMC PMC4985055
Open this paper in CoChat — free account

Abstract

Transforming growth factor-beta (TGF-β) and bone morphogenic protein (BMP) signaling has fundamental roles in both embryonic skeletal development and postnatal bone homeostasis. TGF-βs and BMPs, acting on a tetrameric receptor complex, transduce signals to both the canonical Smad-dependent signaling pathway (that is, TGF-β/BMP ligands, receptors, and Smads) and the non-canonical-Smad-independent signaling pathway (that is, p38 mitogen-activated protein kinase/p38 MAPK) to regulate mesenchymal stem cell differentiation during skeletal development, bone formation and bone homeostasis. Both the Smad and p38 MAPK signaling pathways converge at transcription factors, for example, Runx2 to promote osteoblast differentiation and chondrocyte differentiation from mesenchymal precursor cells. TGF-β and BMP signaling is controlled by multiple factors, including the ubiquitin–proteasome system, epigenetic factors, and microRNA. Dysregulated TGF-β and BMP signaling result in a number of bone disorders in humans. Knockout or mutation of TGF-β and BMP signaling-related genes in mice leads to bone abnormalities of varying severity, which enable a better understanding of TGF-β/BMP signaling in bone and the signaling networks underlying osteoblast differentiation and bone formation. There is also crosstalk between TGF-β/BMP signaling and several critical cytokines’ signaling pathways (for example, Wnt, Hedgehog, Notch, PTHrP, and FGF) to coordinate osteogenesis, skeletal development, and bone homeostasis. This review summarizes the recent advances in our understanding of TGF-β/BMP signaling in osteoblast differentiation, chondrocyte differentiation, skeletal development, cartilage formation, bone formation, bone homeostasis, and related human bone diseases caused by the disruption of TGF-β/BMP signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/boneres.2016.9

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 256

  1. Guo X, Wang XF . Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res 2009; 19: 71–88. · DOI
  2. Feng XH, Derynck R . Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21: 659–693. · DOI · Paper page
  3. Bernabeu C, Lopez-Novoa JM, Quintanilla M . The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 2009; 1792: 954–973. · DOI
  4. Chen G, Deng C, Li YP . TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012; 8: 272–288. · DOI · Paper page
  5. Berendsen AD, Olsen BR . Bone development. Bone 2015; 80: 14–18. · DOI
  6. Long F, Ornitz DM . Development of the endochondral skeleton. Cold Spring Harb Perspect Biol 2013; 5: a008334. · DOI
  7. Crane JL, Xian L, Cao X . Role of TGF-β signaling in coupling bone remodeling. Methods Mol Biol 2016; 1344: 287–300. · DOI
  8. Tang Y, Wu X, Lei W et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009; 15: 757–765. · DOI · Paper page
  9. Li YP, Chen W, Stashenko P . Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit. Biochem Biophys Res Commun 1996; 218: 813–821. · DOI
  10. Li YP, Chen W, Liang Y et al. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 1999; 23: 447–451. · DOI
  11. Chen W, Yang S, Abe Y et al. Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence. Hum Mol Genet 2007; 16: 410–423. · DOI
  12. Li YP, Alexander M, Wucherpfenni AL et al. Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas. J Bone Miner Res 1995; 8: 1197–1202.
  13. Razzouk S, Sarkis R . BMP-2: biological challenges to its clinical use. N Y State Dent J 2012; 78: 37–39.
  14. Kanakaris NK, Giannoudis PV . Clinical applications of bone morphogenetic proteins: current evidence. J Surg Orthop Adv 2008; 17: 133–146.
  15. Zhang W, Zhou M, Liu C et al. A novel mutation of SMAD3 identified in a Chinese family with aneurysms-osteoarthritis syndrome. BioMed Res Int 2015; 2015: 1–6.
  16. Dodd AW, Syddall CM, Loughlin J . A rare variant in the osteoarthritis-associated locus GDF5 is functional and reveals a site that can be manipulated to modulate GDF5 expression. Eur J Hum Genet 2013; 21: 517–521. · DOI
  17. van der Kraan PM, Goumans MJ, Blaney Davidson E et al. Age-dependent alteration of TGF-β signalling in osteoarthritis. Cell Tissue Res 2012; 347: 257–265. · DOI
  18. Hayashi M, Muneta T, Ju YJ et al. Weekly intra-articular injections of bone morphogenetic protein-7 inhibits osteoarthritis progression. Arthritis Res Ther 2008; 10: R118. · DOI
  19. Blaney Davidson EN, van der Kraan PM, van den Berg WB . TGF-beta and osteoarthritis. Osteoarthritis Cartilage 2007; 15: 597–604. · DOI
  20. van den Bosch MH, Blom AB, van Lent PL et al. Canonical Wnt signaling skews TGF-β signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8. Cell Signal 2014; 26: 951–958. · DOI
  21. Sakou T, Onishi T, Yamamoto T et al. Localization of Smads, the TGF-β family intracellular signaling components during endochondral ossification. J Bone Miner Res 1999; 14: 1145–1152. · DOI
  22. Serra R, Karaplis A, Sohn P . Parathyroid hormone-related peptide (PTHrP)-dependent and -independent effects of transforming growth factor beta (TGF-beta) on endochondral bone formation. J Cell Biol 1999; 145: 783–794. · DOI
  23. Li TF, O'Keefe RJ, Chen D . TGF-beta signaling in chondrocytes. Front Biosci 2005; 10: 681–688. · DOI
  24. Sanford LP, Ormsby I, Gittenberger-de Groot AC et al. TGF beta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997; 124: 2659–2670. · DOI · Paper page
  25. Kulkarni AB, Huh CG, Becker D et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90: 770–774. · DOI · Paper page
  26. Kaartinen V, Voncken JW, Shuler C et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995; 11: 415–421. · DOI
  27. Proetzel G, Pawlowski SA, Wiles MV et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 1995; 11: 409–414. · DOI
  28. Crane JL, Cao X . Bone marrow mesenchymal stem cells and TGF-β signaling in bone remodeling. J Clin Invest 2014; 124: 466–472. · DOI
  29. Karsdal MA, Larsen L, Engsig MT et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 2002; 277: 44061–44067. · DOI
  30. Matsunobu T, Torigoe K, Ishikawa M et al. Critical roles of the TGF-beta type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development. Dev Biol 2009; 332: 325–338. · DOI
  31. Yasui T, Kadono Y, Nakamura M et al. Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6. J Bone Miner Res 2011; 26: 1447–1456. · DOI
  32. Leah E . Osteoarthritis: TGF-β overload at bones of cartilage degeneration. Nat Rev Rheumatol 2013; 9: 382. · DOI
  33. Serra R, Johnson M, Filvaroff EH et al. Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol 1997; 139: 541–552. · DOI
  34. Bush JR, Beier F . TGF-β and osteoarthritis--the good and the bad. Nat Med 2013; 19: 667–669. · DOI
  35. van der Kraan PM . Age-related alterations in TGF beta signaling as a causal factor of cartilage degeneration in osteoarthritis. Biomed Mater Eng 2014; 24 1 Suppl: 75–80.
  36. Zhen G, Wen C, Jia X et al. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med 2013; 19: 704–712. · DOI
  37. Xu X, Zheng L, Bian Q et al. Aberrant activation of TGF-β in subchondral bone at the onset of rheumatoid arthritis joint destruction. J Bone Miner Res 2015; 30: 2033–2043. · DOI
  38. Dabovic B, Levasseur R, Zambuto L et al. Osteopetrosis-like phenotype in latent TGF-beta binding protein 3 deficient mice. Bone 2005; 37: 25–31. · DOI
  39. Koli K, Ryynänen MJ, Keski-Oja J . Latent TGF-beta binding proteins (LTBPs)-1 and -3 coordinate proliferation and osteogenic differentiation of human mesenchymal stem cells. Bone 2008; 43: 679–688. · DOI
  40. Nikitovic D, Aggelidakis J, Young MF et al. The biology of small leucine-rich proteoglycans in bone pathophysiology. J Biol Chem 2012; 287: 33926–33933. · DOI
  41. Grafe I, Yang T, Alexander S et al. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta. Nat Med 2014; 20: 670–675. · DOI
  42. Qiu T, Wu X, Zhang F et al. TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat Cell Biol 2010; 12: 224–234. · DOI
  43. Longobardi L, Li T, Myers TJ et al. TGF-β type II receptor/MCP-5 axis: at the crossroad between joint and growth plate development. Dev Cell 2012; 23: 71–81. · DOI
  44. Spagnoli A, O'Rear L, Chandler RL et al. TGF-beta signaling is essential for joint morphogenesis. J Cell Biol 2007; 177: 1105–1117. · DOI
  45. Seo HS, Serra R . Deletion of Tgfbr2 in Prx1-cre expressing mesenchyme results in defects in development of the long bones and joints. Dev Biol 2007; 310: 304–316. · DOI
  46. Baffi MO, Slattery E, Sohn P et al. Conditional deletion of the TGF-beta type II receptor in Col2a expressing cells results in defects in the axial skeleton without alterations in chondrocyte differentiation or embryonic development of long bones. Dev Biol 2004; 276: 124–142. · DOI
  47. Kang JS, Alliston T, Delston R et al. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J 2005; 24: 2543–2555. · DOI
  48. Alliston T, Choy L, Ducy P et al. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 2001; 20: 2254–2272. · DOI · Paper page
  49. Hjelmeland AB, Schilling SH, Guo X et al. Loss of Smad3-mediated negative regulation of Runx2 activity leads to an alteration in cell fate determination. Mol Cell Biol 2005; 25: 9460–9468. · DOI
  50. Li J, Tsuji K, Komori T et al. Smad2 overexpression enhances Smad4 gene expression and suppresses CBFA1 gene expression in osteoblastic osteosarcoma ROS17/2.8 cells and primary rat calvaria cells. J Biol Chem 1998; 273: 31009–31015. · DOI
  51. Borton AJ, Frederick JP, Datto MB et al. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res 2001; 16: 1754–1764. · DOI
  52. Kaji H, Naito J, Sowa H et al. Smad3 differently affects osteoblast differentiation depending upon its differentiation stage. Horm Metab Res 2006; 38: 740–745. · DOI
  53. Ferguson CM, Schwarz EM, Reynolds PR et al. Smad2 and 3 mediate transforming growth factor-beta1-induced inhibition of chondrocyte maturation. Endocrinology 2000; 141: 4728–4735. · DOI
  54. Alvarez J, Serra R . Unique and redundant roles of Smad3 in TGF-beta-mediated regulation of long bone development in organ culture. Dev Dyn 2004; 230: 685–699. · DOI
  55. Li TF, Darowish M, Zuscik MJ et al. Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation. J Bone Miner Res 2006; 21: 4–16. · DOI
  56. Ashcroft GS, Yang X, Glick AB et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1999; 1: 260–266. · DOI · Paper page
  57. Chen CG, Thuillier D, Chin EN et al. Chondrocyte-intrinsic Smad3 represses Runx2-inducible matrix metalloproteinase 13 expression to maintain articular cartilage and prevent osteoarthritis. Arthritis Rheum 2012; 64: 3278–3289. · DOI
  58. Yang X, Chen L, Xu X et al. TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J Cell Biol 2001; 153: 35–46. · DOI
  59. van de Laar IM, Oldenburg RA, Pals G et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 2011; 43: 121–126. · DOI
  60. van de Laar IM, van der Linde D, Oei EH et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet 2012; 49: 47–57. · DOI
  61. Lee KS, Hong SH, Bae SC . Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-β and bone morphogenetic protein. Oncogene 2002; 21: 7156–7163. · DOI
  62. Lai CF, Cheng SL . Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-beta in normal human osteoblastic cells. J Biol Chem 2002; 277: 15514–15522. · DOI
  63. Luu HH, Song WX, Luo X et al. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res 2007; 25: 665–677. · DOI
  64. Abula K, Muneta T, Miyatake K et al. Elimination of BMP7 from the developing limb mesenchyme leads to articular cartilage degeneration and synovial inflammation with increased age. FEBS Lett 2015; 589: 1240–1248. · DOI
  65. Huang Z, Ren PG, Ma T et al. Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability. Cytokine 2010; 51: 305–310. · DOI
  66. Noël D, Gazit D, Bouquet C et al. Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cells. Stem Cells 2004; 22: 74–85. · DOI
  67. Gu K, Zhang L, Jin T et al. Identification of potential modifiers of Runx2/Cbfa1 activity in C2C12 cells in response to bone morphogenetic protein-7. Cells Tissues Organs (Print) 2004; 176: 28–40. · DOI
  68. Shen B, Wei A, Whittaker S et al. The role of BMP-7 in chondrogenic and osteogenic differentiation of human bone marrow multipotent mesenchymal stromal cells in vitro. J Cell Biochem 2010; 109: 406–416. · DOI
  69. Tsuji K, Cox K, Gamer L et al. Conditional deletion of BMP7 from the limb skeleton does not affect bone formation or fracture repair. J Orthop Res 2010; 28: 384–389. · DOI
  70. Kokabu S, Gamer L, Cox K et al. BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b. Mol Endocrinol 2012; 26: 87–94. · DOI
  71. Daluiski A, Engstrand T, Bahamonde ME et al. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 2001; 27: 84–88. · DOI
  72. Gamer LW, Cox K, Carlo JM et al. Overexpression of BMP3 in the developing skeleton alters endochondral bone formation resulting in spontaneous rib fractures. Dev Dyn 2009; 238: 2374–2381. · DOI
  73. Chan CK, Seo EY, Chen JY et al. Identification and specification of the mouse skeletal stem cell. Cell 2015; 160: 285–298. · DOI
  74. Worthley DL, Churchill M, Compton JT et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell 2015; 160: 269–284. · DOI
  75. Minina E, Kreschel C, Naski MC et al. Interaction of FGF, IHH/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell 2002; 3: 439–449. · DOI
  76. Kobayashi T, Lyons KM, McMahon AP et al. BMP signaling stimulates cellular differentiation at multiple steps during cartilage development. Proc Natl Acad Sci USA 2005; 102: 18023–18027. · DOI
  77. Komatsu Y, Kaartinen V, Mishina Y . Cell cycle arrest in node cells governs ciliogenesis at the node to break left-right symmetry. Development 2011; 138: 3915–3920. · DOI
  78. Haas AR, Tuan RS . Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: II. Stimulation by bone morphogenetic protein-2 requires modulation of N-cadherin expression and function. Differentiation 1999; 64: 77–89. · DOI
  79. Luo G, Hofmann C, Bronckers AL et al. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev 1995; 9: 2808–2820. · DOI
  80. Selever J, Liu W, Lu MF et al. Bmp4 in limb bud mesoderm regulates digit pattern by controlling AER development. Dev Biol 2004; 276: 268–279. · DOI
  81. Bandyopadhyay A, Tsuji K, Cox K et al. Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. PLoS Genet 2006; 2: e216. · DOI
  82. Tsuji K, Bandyopadhyay A, Harfe BD et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 2006; 38: 1424–1429. · DOI
  83. Tsuji K, Cox K, Bandyopadhyay A et al. BMP4 is dispensable for skeletogenesis and fracture-healing in the limb. J Bone Joint Surg Am 2008; 90 Suppl 1: 14–18. · DOI
  84. Long F . Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 2012; 13: 27–38. · DOI
  85. Shu B, Zhang M, Xie R et al. BMP2, but not BMP4, is crucial for chondrocyte proliferation and maturation during endochondral bone development. J Cell Sci 2011; 124 Pt 20: 3428–3440. · DOI
  86. Sekiya I, Tang T, Hayashi M et al. Periodic knee injections of BMP-7 delay cartilage degeneration induced by excessive running in rats. J Orthop Res 2009; 27: 1088–1092. · DOI
  87. Takahashi T, Muneta T, Tsuji K et al. BMP-7 inhibits cartilage degeneration through suppression of inflammation in rat zymosan-induced arthritis. Cell Tissue Res 2011; 344: 321–332. · DOI
  88. Rountree RB, Schoor M, Chen H et al. BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol 2004; 2: e355. · DOI
  89. Medici D, Shore EM, Lounev VY et al. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 2010; 16: 1400–1406. · DOI
  90. Shore EM, Xu M, Feldman GJ et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006; 38: 525–527. · DOI
  91. Shen Q, Little SC, Xu M et al. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest 2009; 119: 3462–3472.
  92. van Dinther M, Visser N, de Gorter DJ et al. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 2010; 25: 1208–1215. · DOI
  93. Yang C, Yang L, Wan M et al. Generation of a mouse model with expression of bone morphogenetic protein type II receptor lacking the cytoplasmic domain in osteoblasts. Ann N Y Acad Sci 2010; 1192: 286–291. · DOI
  94. Mishina Y, Starbuck MW, Gentile MA et al. Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling. J Biol Chem 2004; 279: 27560–27566. · DOI
  95. Kamiya N, Kobayashi T, Mochida Y et al. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res 2010; 25: 200–210. · DOI · Paper page
  96. Kamiya N, Ye L, Kobayashi T et al. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res 2008; 23: 2007–2017. · DOI
  97. Kamiya N, Ye L, Kobayashi T et al. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 2008; 135: 3801–3811. · DOI
  98. Dewulf N, Verschueren K, Lonnoy O et al. Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis. Endocrinology 1995; 136: 2652–2663. · DOI
  99. Francis PH, Richardson MK, Brickell PM et al. Bone morphogenetic proteins and a signalling pathway that controls patterning in the developing chick limb. Development 1994; 120: 209–218. · DOI
  100. Kawakami Y, Ishikawa T, Shimabara M et al. BMP signaling during bone pattern determination in the developing limb. Development 1996; 122: 3557–3566. · DOI
  101. Yamaji N, Celeste AJ, Thies RS et al. A mammalian serine/threonine kinase receptor specifically binds BMP-2 and BMP-4. Biochem Biophys Res Commun 1994; 205: 1944–1951. · DOI
  102. Zou H, Wieser R, Massagué J et al. Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes Dev 1997; 11: 2191–2203. · DOI
  103. Yoon BS, Ovchinnikov DA, Yoshii I et al. Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 5062–5067. · DOI
  104. Rigueur D, Brugger S, Anbarchian T et al. The type I BMP receptor ACVR1/ALK2 is required for chondrogenesis during development. J Bone Miner Res 2015; 30: 733–741. · DOI
  105. Enomoto-Iwamoto M, Iwamoto M, Mukudai Y et al. Bone morphogenetic protein signaling is required for maintenance of differentiated phenotype, control of proliferation, and hypertrophy in chondrocytes. J Cell Biol 1998; 140: 409–418. · DOI
  106. Fujii M, Takeda K, Imamura T et al. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell 1999; 10: 3801–3813. · DOI
  107. Zhang D, Schwarz EM, Rosier RN et al. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Miner Res 2003; 18: 1593–1604. · DOI
  108. Yi SE, Daluiski A, Pederson R et al. The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development 2000; 127: 621–630. · DOI
  109. Yoon BS, Pogue R, Ovchinnikov DA et al. BMPs regulate multiple aspects of growth-plate chondrogenesis through opposing actions on FGF pathways. Development 2006; 133: 4667–4678. · DOI
  110. Afzal F, Pratap J, Ito K et al. Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol 2005; 204: 63–72. · DOI
  111. Franceschi RT, Xiao G . Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 2003; 88: 446–454. · DOI
  112. Wang M, Jin H, Tang D et al. Smad1 plays an essential role in bone development and postnatal bone formation. Osteoarthritis Cartilage 2011; 19: 751–762. · DOI
  113. Keller B, Yang T, Chen Y et al. Interaction of TGFβ and BMP signaling pathways during chondrogenesis. PLoS One 2011; 6: e16421. · DOI
  114. Retting KN, Song B, Yoon BS et al. BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation. Development 2009; 136: 1093–1104. · DOI
  115. Matsumoto Y, Otsuka F, Hino J et al. Bone morphogenetic protein-3b (BMP-3b) inhibits osteoblast differentiation via Smad2/3 pathway by counteracting Smad1/5/8 signaling. Mol Cell Endocrinol 2012; 350: 78–86. · DOI
  116. Ishibashi N, Sasaki Y, Asakura Y . Myhre syndrome: a rare craniofacial disorder. Cranio 2014; 32: 300–306. · DOI
  117. Le Goff C, Mahaut C, Abhyankar A et al. Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome. Nat Genet 2012; 44: 85–88. · DOI
  118. Nojima J, Kanomata K, Takada Y et al. Dual roles of smad proteins in the conversion from myoblasts to osteoblastic cells by bone morphogenetic proteins. J Biol Chem 2010; 285: 15577–15586. · DOI
  119. Zhang J, Tan X, Li W et al. Smad4 is required for the normal organization of the cartilage growth plate. Dev Biol 2005; 284: 311–322. · DOI
  120. Tan X, Weng T, Zhang J et al. Smad4 is required for maintaining normal murine postnatal bone homeostasis. J Cell Sci 2007; 120: 2162–2170. · DOI
  121. Salazar VS, Zarkadis N, Huang L et al. Embryonic ablation of osteoblast Smad4 interrupts matrix synthesis in response to canonical Wnt signaling and causes an osteogenesis-imperfecta-like phenotype. J Cell Sci 2013; 126 (Pt 21): 4974–4984.
  122. Salazar VS, Zarkadis N, Huang L et al. Postnatal ablation of osteoblast Smad4 enhances proliferative responses to canonical Wnt signaling through interactions with β-catenin. J Cell Sci 2013; 126 (Pt 24): 5598–5609.
  123. Billings PC, Fiori JL, Bentwood JL et al. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2008; 23: 305–313. · DOI
  124. Gunnell LM, Jonason JH, Loiselle AE et al. TAK1 regulates cartilage and joint development via the MAPK and BMP signaling pathways. J Bone Miner Res 2010; 25: 1784–1797. · DOI
  125. Gao L, Sheu TJ, Dong Y et al. TAK1 regulates SOX9 expression in chondrocytes and is essential for postnatal development of the growth plate and articular cartilages. J Cell Sci 2013; 126 (Pt 24): 5704–5713.
  126. Greenblatt MB, Shim JH, Zou W et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest 2010; 120: 2457–2473. · DOI
  127. Ge C, Yang Q, Zhao G et al. Interactions between extracellular signal-regulated kinase 1/2 and p38 MAP kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity. J Bone Miner Res 2012; 27: 538–551. · DOI
  128. Ulsamer A, Ortuño MJ, Ruiz S et al. BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. J Biol Chem 2008; 283: 3816–3826. · DOI
  129. Ortuno MJ, Ruiz-Gaspa S, Rodriguez-Carballo E et al. p38 Regulates Expression of Osteoblast-specific Genes by Phosphorylation of Osterix. J Biol Chem 2010; 285: 31985–31994. · DOI
  130. Celil AB, Hollinger JO, Campbell PG . Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signaling. J Cell Biochem 2005; 95: 518–528. · DOI
  131. Choi YH, Gu YM, Oh JW et al. Osterix is regulated by Erk1/2 during osteoblast differentiation. Biochem Biophys Res Commun 2011; 415: 472–478. · DOI
  132. Gazzerro E, Gangji V, Canalis E . Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 1998; 102: 2106–2114. · DOI
  133. Abe E, Yamamoto M, Taguchi Y et al. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res 2000; 15: 663–673. · DOI
  134. Wan DC, Pomerantz JH, Brunet LJ et al. Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem 2007; 282: 26450–26459. · DOI
  135. Glaser DL, Economides AN, Wang L et al. In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am 2003; 85-A: 2332–2342. · DOI
  136. Wang Y, Hong S, Li M et al. Noggin resistance contributes to the potent osteogenic capability of BMP9 in mesenchymal stem cells. J Orthop Res 2013; 31: 1796–1803. · DOI
  137. Gong Y, Krakow D, Marcelino J et al. Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis. Nat Genet 1999; 21: 302–304. · DOI
  138. Wijgerde M, Karp S, McMahon J et al. Noggin antagonism of BMP4 signaling controls development of the axial skeleton in the mouse. Dev Biol 2005; 286: 149–157. · DOI
  139. Stafford DA, Brunet LJ, Khokha MK et al. Cooperative activity of noggin and gremlin 1 in axial skeleton development. Development 2011; 138: 1005–1014. · DOI
  140. Stafford DA, Monica SD, Harland RM . Follistatin interacts with Noggin in the development of the axial skeleton. Mech Dev 2014; 131: 78–85. · DOI
  141. Devlin RD, Du Z, Pereira RC et al. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 2003; 144: 1972–1978. · DOI
  142. Wu XB, Li Y, Schneider A et al. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest 2003; 112: 924–934. · DOI
  143. Pathi S, Rutenberg JB, Johnson RL et al. Interaction of IHH and BMP/Noggin signaling during cartilage differentiation. Dev Biol 1999; 209: 239–253. · DOI
  144. Warren SM, Brunet LJ, Harland RM et al. The BMP antagonist noggin regulates cranial suture fusion. Nature 2003; 422: 625–629. · DOI
  145. Zehentner BK, Haussmann A, Burtscher H . The bone morphogenetic protein antagonist Noggin is regulated by Sox9 during endochondral differentiation. Dev Growth Differ 2002; 44: 1–9. · DOI
  146. Kalajzic I, Kalajzic Z, Hurley MM et al. Stage specific inhibition of osteoblast lineage differentiation by FGF2 and noggin. J Cell Biochem 2003; 88: 1168–1176. · DOI
  147. Reinhold MI, Abe M, Kapadia RM et al. FGF18 represses noggin expression and is induced by calcineurin. J Biol Chem 2004; 279: 38209–38219. · DOI
  148. Nakayama N, Han CE, Scully S et al. A novel chordin-like protein inhibitor for bone morphogenetic proteins expressed preferentially in mesenchymal cell lineages. Dev Biol 2001; 232: 372–387. · DOI
  149. Oren A, Toporik A, Biton S et al. hCHL2, a novel chordin-related gene, displays differential expression and complex alternative splicing in human tissues and during myoblast and osteoblast maturation. Gene 2004; 331: 17–31. · DOI
  150. Nakayama N, Han CY, Cam L et al. A novel chordin-like BMP inhibitor, CHL2, expressed preferentially in chondrocytes of developing cartilage and osteoarthritic joint cartilage. Development 2004; 131: 229–240. · DOI
  151. Petryk A, Shimmi O, Jia XH et al. Twisted gastrulation and chordin inhibit differentiation and mineralization in MC3T3-E1 osteoblast-like cells. Bone 2005; 36: 617–626. · DOI
  152. Zhang D, Ferguson CM, O'Keefe RJ et al. A role for the BMP antagonist chordin in endochondral ossification. J Bone Miner Res 2002; 17: 293–300. · DOI
  153. Anderson RM, Lawrence AR, Stottmann RW et al. Chordin and noggin promote organizing centers of forebrain development in the mouse. Development 2002; 129: 4975–4987. · DOI
  154. Yan X, Liu Z, Chen Y . Regulation of TGF-beta signaling by Smad7. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 263–272. · DOI
  155. Moustakas A, Heldin CH . The regulation of TGF signal transduction. Development 2009; 136: 3699–3714. · DOI
  156. Scharstuhl A, Diepens R, Lensen J et al. Adenoviral overexpression of Smad-7 and Smad-6 differentially regulates TGF-beta-mediated chondrocyte proliferation and proteoglycan synthesis. Osteoarthritis Cartilage 2003; 11: 773–782. · DOI
  157. Valcourt U, Gouttenoire J, Moustakas A et al. Functions of transforming growth factor-beta family type I receptors and Smad proteins in the hypertrophic maturation and osteoblastic differentiation of chondrocytes. J Biol Chem 2002; 277: 33545–33558. · DOI
  158. Li X, Ionescu AM, Schwarz EM et al. Smad6 is induced by BMP-2 and modulates chondrocyte differentiation. J Orthop Res 2003; 21: 908–913. · DOI
  159. Yano M, Inoue Y, Tobimatsu T et al. Smad7 inhibits differentiation and mineralization of mouse osteoblastic cells. Endocr J 2012; 59: 653–662. · DOI
  160. Horiki M, Imamura T, Okamoto M et al. Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes dwarfism with osteopenia. J Cell Biol 2004; 165: 433–445. · DOI
  161. Shen R, Chen M, Wang YJ et al. Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. J Biol Chem 2006; 281: 3569–3576. · DOI
  162. Wang Q, Wei X, Zhu T et al. Bone morphogenetic protein 2 activates Smad6 gene transcription through bone-specific transcription factor Runx2. J Biol Chem 2007; 282: 10742–10748. · DOI
  163. Iwai T, Murai J, Yoshikawa H et al. Smad7 Inhibits chondrocyte differentiation at multiple steps during endochondral bone formation and down-regulates p38 MAPK pathways. J Biol Chem 2008; 283: 27154–27164. · DOI
  164. Wu Q, Wang M, Zuscik MJ et al. Regulation of embryonic endochondral ossification by Smurf2. J Orthop Res 2008; 26: 704–712. · DOI
  165. Yamashita M, Ying SX, Zhang GM et al. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 2005; 121: 101–113. · DOI
  166. Qi H, Jin M, Duan Y et al. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development. Biochim Biophys Acta 2014; 1843: 1237–1247. · DOI
  167. Tsubakihara Y, Hikita A, Yamamoto S et al. Arkadia enhances BMP signalling through ubiquitylation and degradation of Smad6. J Biochem 2015; 158: 61–71. · DOI
  168. Shimada K, Suzuki N, Ono Y et al. Ubc9 promotes the stability of Smad4 and the nuclear accumulation of Smad1 in osteoblast-like Saos-2 cells. Bone 2008; 42: 886–893. · DOI
  169. Yukita A, Hosoya A, Ito Y et al. Ubc9 negatively regulates BMP-mediated osteoblastic differentiation in cultured cells. Bone 2012; 50: 1092–1099. · DOI
  170. Herhaus L, Al-Salihi MA, Dingwell KS et al. USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling. Open Biol 2014; 4: 140065. · DOI
  171. Kawamura I, Maeda S, Imamura K et al. SnoN suppresses maturation of chondrocytes by mediating signal cross-talk between transforming growth factor-β and bone morphogenetic protein pathways. J Biol Chem 2012; 287: 29101–29113. · DOI
  172. Usui M, Yoshida Y, Tsuji K et al. Tob deficiency superenhances osteoblastic activity after ovariectomy to block estrogen deficiency-induced osteoporosis. Proc Natl Acad Sci USA 2004; 101: 6653–6658. · DOI
  173. Yoshida Y, Tanaka S, Umemori H et al. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 2000; 103: 1085–1097. · DOI
  174. Li Z, Hassan MQ, Volinia S et al. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci USA 2008; 105: 13906–13911. · DOI
  175. Balderman JAF, Lee HY, Mahoney CE et al. Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification. J Am Heart Assoc 2012; 1: e003905–e003905. · DOI
  176. Wu T, Zhou H, Hong Y et al. miR-30 family members negatively regulate osteoblast differentiation. J Biol Chem 2012; 287: 7503–7511. · DOI
  177. Gámez B, Rodríguez-Carballo E, Bartrons R et al. MicroRNA-322 (miR-322) and its target protein Tob2 modulate Osterix (Osx) mRNA stability. J Biol Chem 2013; 288: 14264–14275. · DOI
  178. Itoh T, Nozawa Y, Akao Y . MicroRNA-141 and -200a are involved in bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less homeobox 5. J Biol Chem 2009; 284: 19272–19279. · DOI
  179. Kureel J, Dixit M, Tyagi AM et al. miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation. Cell Death Dis 2014; 5: e1050. · DOI
  180. Zhang JF, Fu WM, He ML et al. MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol 2011; 8: 829–838. · DOI
  181. Nakamura Y, Inloes JB, Katagiri T et al. Chondrocyte-specific microRNA-140 regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein signaling. Mol Cell Biol 2011; 31: 3019–3028. · DOI · Paper page
  182. Borgonio Cuadra VM, González-Huerta NC, Romero-Córdoba S et al. Altered expression of circulating microRNA in plasma of patients with primary osteoarthritis and in silico analysis of their pathways. PLoS One 2014; 9: e97690. · DOI
  183. Díaz-Prado S, Cicione C, Muiños-López E et al. Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes. BMC Musculoskelet Disord 2012; 13: 144. · DOI
  184. Tew SR, Vasieva O, Peffers MJ et al. Post-transcriptional gene regulation following exposure of osteoarthritic human articular chondrocytes to hyperosmotic conditions. Osteoarthritis Cartilage 2011; 19: 1036–1046. · DOI
  185. Jin L, Zhao J, Jing W et al. Role of miR-146a in human chondrocyte apoptosis in response to mechanical pressure injury in vitro. Int J Mol Med 2014; 34: 451–463. · DOI
  186. Li J, Huang J, Dai L et al. miR-146a, an IL-1β responsive miRNA, induces vascular endothelial growth factor and chondrocyte apoptosis by targeting Smad4. Arthritis Res Ther 2012; 14: R75. · DOI
  187. Lin EA, Kong L, Bai XH et al. miR-199a, a bone morphogenic protein 2-responsive microRNA, regulates chondrogenesis via direct targeting to Smad1. J Biol Chem 2009; 284: 11326–11335. · DOI
  188. Furumatsu T, Asahara H . Histone acetylation influences the activity of Sox9-related transcriptional complex. Acta Med Okayama 2010; 64: 351–357.
  189. Lee HL, Yu B, Deng P et al. Transforming growth factor-β-induced KDM4B promotes chondrogenic differentiation of human mesenchymal. Stem Cells 2016; 34: 711–719. · DOI
  190. Lee ZH, Kim HJ, Ryoo HM . A novel osteogenic activity of suberoylanilide hydroxamic acid is synergized by BMP-2. J Bone Metab 2015; 22: 51–56. · DOI
  191. Cho YD, Yoon WJ, Kim WJ et al. Epigenetic modifications and canonical wingless/int-1 class (WNT) signaling enable trans-differentiation of nonosteogenic cells into osteoblasts. J Biol Chem 2014; 289: 20120–20128. · DOI
  192. Zhou S, Eid K, Glowacki J . Cooperation between TGF-β and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. J Bone Miner Res 2003; 19: 463–470. · DOI
  193. Dao DY, Yang X, Chen D et al. Axin1 and Axin2 are regulated by TGF- and mediate cross-talk between TGF- and Wnt signaling pathways. Ann NY Acad Sci 2007; 1116: 82–99. · DOI
  194. McCarthy TL, Centrella M . Novel links among Wnt and TGF-beta signaling and Runx2. Mol Endocrinol 2010; 24: 587–597. · DOI
  195. Liu Z, Tang Y, Qiu T et al. A dishevelled-1/Smad1 interaction couples WNT and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells. J Biol Chem 2006; 281: 17156–17163. · DOI
  196. Rawadi G, Vayssière B, Dunn F et al. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003; 18: 1842–1853. · DOI
  197. Zhang M, Yan Y, Lim YB et al. BMP-2 modulates beta-catenin signaling through stimulation of Lrp5 expression and inhibition of beta-TrCP expression in osteoblasts. J Cell Biochem 2009; 108: 896–905. · DOI
  198. Papathanasiou I, Malizos KN, Tsezou A . Bone morphogenetic protein-2-induced Wnt/β-catenin signaling pathway activation through enhanced low-density-lipoprotein receptor-related protein 5 catabolic activity contributes to hypertrophy in osteoarthritic chondrocytes. Arthritis Res Ther 2012; 14: R82. · DOI
  199. Tang N, Song WX, Luo J et al. BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. J Cell Mol Med 2009; 13: 2448–2464. · DOI
  200. Rodríguez-Carballo E, Ulsamer A, Susperregui AR et al. Conserved regulatory motifs in osteogenic gene promoters integrate cooperative effects of canonical Wnt and BMP pathways. J Bone Miner Res 2011; 26: 718–729. · DOI

200 of 256 shown

Cited by

Sorted by citations

See all 1,553

Metadata

Authors
Wu, M., Chen, G., & Li, Y.-P.
Venue
Bone Research
Publisher
Springer Science and Business Media LLC
Published
2016-04-26
Volume
4
Issue
1
ISSN
2095-6231
DOI
10.1038/boneres.2016.9
PMC
PMC4985055
Cited by
1,553
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review